Marino Garcia says his prior dealmaking experience was very important during Dianthus's reverse merger because he understood how intense diligence can be, how to prepare his team, and what the other side was looking for. He also had to run a financing alongside the process.
Marino Garcia says existing complement therapies are infusions or frequent injections that shut down the whole complement system and carry box warnings. Dianthus aims for an infrequent self-administered therapy so treatment can fit patients' lives instead of forcing patients to adjust their lives. That is the goal for next-step complement drugs.
Marino Garcia says small biotech carries more risk than Big Pharma but it gives people empowerment and visible daily impact. Dianthus competes by focusing every day on moving faster, and he says investors praise the company for doing everything it promised and more. That execution comes back to hiring the right team.
Marino Garcia strongly recommends every CEO hire an outside coach they trust and speak with weekly. He says the coach should be very different from the CEO and willing to tell the CEO they are wrong; he even makes his coach available to executives. That outside pushback has been invaluable to him.
Marino Garcia says after 30 years he can tell quickly whether a biotech leadership team loves the science and mechanism or loves patient impact. He also asks whether leaders inspire employees or just pay them to hit milestones before a sale. That distinction, he says, separates successful biotech companies from less successful ones.
Marino Garcia says Dianthus waited for Phase 1 PKPD data showing a long half-life and potent classical-pathway shutdown before entering the Magenta reverse merger. He credits the clinical development operations team for giving Magenta confidence that Dianthus could execute. The combination of data and people made the critical moment come together.
Marino Garcia says Big Pharma has scale for large multinational trials and global launches. But he argues biotech's edge is strategic focus, execution, and speed, and with investor support Dianthus can do what a Big Pharma can do and do it better. That focus, he says, matters.
